Nordea Investment Management 13F: Cuts BDX Stake by $165M
Nordea Investment Management trimmed its Becton, Dickinson holdings by 31%, as per recent 13F filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Nordea Investment Management sold 1,092,124 shares from its stake in Becton, Dickinson and Company ($BDX), a 30.96% decrease, according to a 13F filing with the SEC dated May 13, 2026. It reported 2,435,206 shares worth $368.52 million at the end of the quarter.
Since the filing, $BDX is up 1.9% after 1 week, up 2.1% after 1 month and up 34.7% to date (from the $142.33 close on May 13, 2026).
Find the original: Nordea Investment Management 13F filings on SEC EDGAR
BDX
Becton, Dickinson and Company
Key Points
- Nordea Investment Management trimmed its stake in Becton, Dickinson by 31%, selling 1,092,124 shares to hold 2,435,206 shares worth $350.6 million.
- Becton, Dickinson's stock trades near $143.98 with a market cap of $39.67 billion and a P/E ratio of 25.13.
- Insiders, including CEO Thomas Polen Jr., executed multiple transactions, while analysts maintain mixed ratings with price targets ranging from $159 to $204.
Get $BDX trade alerts by text
We text you when insiders, Congress or big funds trade $BDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Becton, Dickinson and Company alert may contain errors. Disclosures
Nordea Investment Management has cut its stake in Becton, Dickinson and Company (NYSE: BDX) by about 31%, according to its latest 13F filing with the SEC. The firm sold 1,092,124 shares, bringing its total holdings to 2,435,206 shares, valued at roughly $350.6 million as of the reporting period.
Nordea Investment Management vs. the S&P 500
Hypothetical returns from Nordea Investment Management's disclosed trades, not real profit or advice. How we model this.
What Changed in Nordea Investment Management's Becton, Dickinson Position
Nordea Investment Management's recent filing shows a significant reduction in its Becton, Dickinson position. The firm previously held 3,527,330 shares and has reduced this by 1,092,124 shares, a 31% decrease. The remaining 2,435,206 shares are valued at approximately $350.6 million.
Other Institutional Activity in Becton, Dickinson
Other major institutional players also adjusted their positions in Becton, Dickinson. BlackRock, Inc. reduced its holdings by 9,015,742 shares, ending with 26,153,411 shares worth about $4.11 billion. Vanguard Capital Management LLC, on the other hand, increased its position by 18,490,610 shares, resulting in a total of 18,490,610 shares valued at around $2.91 billion. Similarly, Vanguard Portfolio Management LLC added 15,317,242 shares, reaching a total of 15,317,242 shares valued at approximately $2.41 billion. Meanwhile, State Street Corp decreased its stake by 3,971,368 shares, holding 13,822,808 shares worth $2.17 billion.
Becton, Dickinson and Company Stock Down 16.4%
Shares of Becton, Dickinson (NYSE: BDX) are trading near $143.98. The company has a market capitalization of approximately $39.67 billion and a P/E ratio of 25.13. Its forward P/E is 10.75, and it carries a beta of 0.278, indicating lower volatility compared to the market. The stock's 52-week range is between $127.59 and $187.35, with moving averages of $148.96 (50-day) and $154.07 (200-day). Becton, Dickinson has a current ratio of 0.942 and a quick ratio of 0.355, with a debt-to-equity ratio of 71.6.
Recent Earnings
Becton, Dickinson reported revenue of $22.23 billion, reflecting a growth of 5.2%. The company's net margin stands at 5.12%, with a return on equity of 6.67%. Earnings per share came in at $5.73. The company is expected to release its next earnings report on August 6, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Dividend
Becton, Dickinson offers an annual dividend rate of $4.20, yielding 2.89% based on current prices. The dividend payout ratio is 72.95%.
Insider Buying and Selling at Becton, Dickinson and Company
Several insiders have been active in trading Becton, Dickinson shares. On June 10, 2026, EVP & President of Medical Essentials & BioPharma, Michael David Garrison, sold 1,100 shares at an average price of $151.48 under a planned transaction. On June 1, 2026, CEO Thomas Polen Jr. executed multiple transactions, including selling 17,445 shares at $146.15 and 2,764 shares at $146.35, while also purchasing 20,209 shares at $126.16. EVP and President of BDI, Peter Menziuso, acquired 14,258 shares on the same day.
Analysts Set New Price Targets
Analysts have maintained mixed ratings on Becton, Dickinson. On May 11, 2026, Barclays maintained a "buy" rating with a $204 price target. Wells Fargo maintained a "hold" rating with a $161 target on May 8, 2026, and TD Cowen kept a "hold" rating with a $163 target on May 4, 2026. The consensus recommendation is a "buy" with an average target price of $180.69 from 13 analysts.
About Becton, Dickinson and Company
Becton, Dickinson and Company, headquartered in Franklin Lakes, New Jersey, is a global leader in medical technology. The firm develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. Its offerings serve healthcare institutions, life science researchers, and the general public. The company operates through segments like Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences. Led by CEO Thomas E. Polen Jr., Becton, Dickinson employs around 60,000 people worldwide.
Bottom Line
Nordea Investment Management's reduction in its Becton, Dickinson stake is part of its latest 13F filing, reflecting holdings as of the reporting period. Investors track such filings to gauge fund sentiment and strategy shifts. While institutional moves are backward-looking, they offer insights into potential trends and fund management strategies.
Related Filing Alerts
Source: Nordea Investment Management's 13F filing on $BDX (May 13, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Nordea Investment Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts